Antenatal magnesium sulfate to prevent cerebral palsy

Amy K. Keir; Emily Shepherd; Sarah McIntyre; Alice Rumbold; Charlotte Groves; Caroline Crowther; Emily Joy Callander

doi:10.1136/archdischild-2021-321817

Antenatal magnesium sulfate to prevent cerebral palsy

Amy K. Keir, Emily Shepherd, Sarah McIntyre, Alice Rumbold, Charlotte Groves, Caroline Crowther, Emily Joy Callander

Research output: Contribution to journal › Article › Research › peer-review

1 Citation (Scopus)

Abstract

Magnesium sulfate given to women before birth at <30 weeks' gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks' gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society.

Original language	English
Pages (from-to)	225-227
Number of pages	3
Journal	Archives of Disease in Childhood: Fetal and Neonatal Edition
Volume	107
Issue number	2
DOIs	https://doi.org/10.1136/archdischild-2021-321817
Publication status	Published - Mar 2022

Keywords

health services research
neonatology

Access to Document

10.1136/archdischild-2021-321817

Cite this

@article{439750587cde490ca460ea437e1c0d2d,

title = "Antenatal magnesium sulfate to prevent cerebral palsy",

abstract = "Magnesium sulfate given to women before birth at <30 weeks' gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks' gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society. ",

keywords = "health services research, neonatology",

author = "Keir, {Amy K.} and Emily Shepherd and Sarah McIntyre and Alice Rumbold and Charlotte Groves and Caroline Crowther and Callander, {Emily Joy}",

note = "Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2022",

month = mar,

doi = "10.1136/archdischild-2021-321817",

language = "English",

volume = "107",

pages = "225--227",

journal = "Archives of Disease in Childhood: Fetal and Neonatal Edition",

issn = "1359-2998",

publisher = "BMJ",

number = "2",

}

TY - JOUR

T1 - Antenatal magnesium sulfate to prevent cerebral palsy

AU - Keir, Amy K.

AU - Shepherd, Emily

AU - McIntyre, Sarah

AU - Rumbold, Alice

AU - Groves, Charlotte

AU - Crowther, Caroline

AU - Callander, Emily Joy

PY - 2022/3

Y1 - 2022/3

N2 - Magnesium sulfate given to women before birth at <30 weeks' gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks' gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society.

AB - Magnesium sulfate given to women before birth at <30 weeks' gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks' gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society.

KW - health services research

KW - neonatology

UR - http://www.scopus.com/inward/record.url?scp=85109397600&partnerID=8YFLogxK

U2 - 10.1136/archdischild-2021-321817

DO - 10.1136/archdischild-2021-321817

M3 - Article

C2 - 34233908

AN - SCOPUS:85109397600

VL - 107

SP - 225

EP - 227

JO - Archives of Disease in Childhood: Fetal and Neonatal Edition

JF - Archives of Disease in Childhood: Fetal and Neonatal Edition

SN - 1359-2998

IS - 2

ER -

Antenatal magnesium sulfate to prevent cerebral palsy

Abstract

Keywords

Access to Document

Other files and links

Assessing value in maternal healthcare by harnessing the power of data linkage

Cite this

Antenatal magnesium sulfate to prevent cerebral palsy

Abstract

Keywords

Access to Document

Other files and links

Projects

Assessing value in maternal healthcare by harnessing the power of data linkage

Cite this